How much does the Indian version of Pitobrutinib cost? How is the price different from other regions?
Pitobrutinib is not yet available in China, and domestic patients cannot purchase it directly through domestic channels. However, the generic version of pitobrutinib produced in Laos is already on the market and the price is relatively affordable. According to current information, the price of the Laos version is approximately 2000 yuan, and the specification is 50mg*30 tablets. This price has obvious advantages compared with original drugs from other countries, allowing patients to obtain relatively efficient treatment drugs at a lower cost when purchasing.
Compared with the Lao version of the generic drug, the original drug in the U.S. market is much more expensive. Specifically, the price of the original drug is 50mg*30 tablets, which is as high as about 100,000 yuan. Drug pricing in the U.S. market is generally higher, and originator drugs often include brand premiums. Therefore, if American patients do not have medical insurance support, facing such high prices will bring certain financial pressure.

Although India has not launched a generic version of pitobrutinib, the Laos version is competitive in Southeast Asia and is very affordable. In other countries, especially in the European and American markets, the price of original drugs is generally higher, especially in the United States, where the price may reach several times the standard of original drugs. Therefore, compared to the European and American markets, the Lao version of generic drugs provides an affordable option for patients who require long-term treatment.
For domestic patients, although Pitobrutinib has not yet been launched in China, the Lao version of the generic drug can be purchased through legal overseas drug procurement channels. When choosing to purchase, patients need to pay special attention to choosing formal channels to ensure the quality and safety of drugs. The Lao version of generic drugs is basically the same as the original drug in terms of ingredients and efficacy, so it has become one of the first choices for many patients when seeking treatment.
Reference materials:https://www.jaypirca.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)